D.E. Shaw & Co
KZR

D.E. Shaw & Co’s Kezar Life Sciences KZR Stock Holding History

D.E. Shaw & Co’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,684
Closed -$148K – 4725
2024
Q2 		$148K Sell
24,684
-17,259
-41% -$131K ﹤0.01% 4124
2024
Q1 		$378K Buy
41,943
+4,245
+11% +$38.7K ﹤0.01% 3618
2023
Q4 		$357K Buy
37,698
+33,330
+763% +$293K ﹤0.01% 3675
2023
Q3 		$52K Buy
4,368
+1,571
+56% +$27.8K ﹤0.01% 3915
2023
Q2 		$68.5K Buy
+2,797
New +$72.8K ﹤0.01% 3859
2022
Q2 		– Sell
-9,502
Closed -$1.58M – 5559
2022
Q1 		$1.58M Buy
+9,502
New +$1.36M ﹤0.01% 3531

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co's KZR Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 24,684 shares — an estimated $148K sold.

D.E. Shaw & Co first reported a position in KZR in Q1 2022 and held it in 6 quarters. The position peaked at $1.58M in Q1 2022. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 24,684 Kezar Life Sciences shares in Q3 2024, an estimated $148K.
  • D.E. Shaw & Co first reported a position in Kezar Life Sciences in Q1 2022 and held it in 6 quarters.
  • D.E. Shaw & Co's Kezar Life Sciences position peaked at $1.58M in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.